Don't misuse drug patents to curb market entry of legit competitors

06/14/2013 | RxObserver blog

Government-issued patents help protect the significant investments tied to the development of new drugs and should never be abused to prevent the market entry of legitimate competitors, Edward C. Lawrence writes. The practice of brand-name drugmakers putting up questionable regulatory obstacles to delay or prevent the approval of biosimilars causes the public to needlessly pay billions more for prescription treatments yearly and stifles innovation, Lawrence writes.

View Full Article in:

RxObserver blog

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC